Evidence map›Paper›PMID 39375428›Full record

ArticleCommunications biology2024

Generation of human-pig chimeric renal organoids using iPSC technology.

Koki Fujimori, Shuichiro Yamanaka, Kentaro Shimada, Kenji Matsui, Shiho Kawagoe, Takao Kuroda, Atsushi Ikeda, Makoto Inoue, Eiji Kobayashi, Takashi Yokoo

Abstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. The making of cells and organs in xenogeneic animal bioreactor.Signal transduction and targeted therapy · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Koki FujimoriSumitomo Pharma Co. Ltd., Osaka, Japan. koki.fujimori@sumitomo-pharma.co.jp.ORCID 0009-0004-7871-7535
Shuichiro YamanakaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. shu.yamanaka@jikei.ac.jp.ORCID 0000-0002-4741-1005
Kentaro ShimadaSumitomo Pharma Co. Ltd., Osaka, Japan.ORCID 0009-0002-0830-9478
Kenji MatsuiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.ORCID 0000-0003-2897-2285
Shiho KawagoeDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Takao KurodaSumitomo Pharma Co. Ltd., Osaka, Japan.
Atsushi IkedaSumitomo Pharma Co. Ltd., Osaka, Japan.
Makoto InoueSumitomo Pharma Co. Ltd., Osaka, Japan.ORCID 0000-0003-0804-7439
Eiji KobayashiDepartment of Kidney Regenerative Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Takashi YokooDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. tyokoo@jikei.ac.jp.ORCID 0000-0003-1838-7998

Funding

Japan Agency for Medical Research and Development (AMED) 24bm1123036h0002Japan Agency for Medical Research and Development (AMED) 24bm1223003h0003MEXT | Japan Science and Technology Agency (JST) JPMJFR2011
6 · The paper itself

Abstract

Porcine organs and human induced pluripotent stem cell (iPSC)-derived organoids as alternative organs for human transplantation have garnered attention, but both face technical challenges. Interspecies chimeric organ production using human iPSCs shows promise in overcoming these challenges. Our group successfully generated chimeric renal organoids using human iPSC-derived nephron progenitor cells (NPCs) and fetal mouse kidneys. However, the current technology is limited to rodents. Therefore, this study focused on producing human-pig chimeric renal organoids, as pigs are the most promising species for xenotransplantation. Modification of existing culture systems enables continuous renal development in both species, resulting in the successful creation of human-pig chimeric renal organoids. Moreover, this method can be applied to generate humanized xenogeneic kidneys for future clinical applications. This study provides evidence that optimizing culture conditions enables the early-stage kidney development beyond species barriers, thus laying the foundation for accelerating research on humanized xenogeneic kidney fabrication for clinical purposes.

Indexed as

Induced Pluripotent Stem CellsKidneyOrganoidsAnimalsChimeraHumansMiceSwineTransplantation, Heterologous

Identifiers

PMID39375428
PMCPMC11458617

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.